Research Index
Tirzepatide Research Index
PSI surfaces 50 peer-reviewed studies on Tirzepatide, prioritized by evidence strength: human clinical research first, then animal studies. The full historical archive is linked below on PubMed.
50 studies
[Non-arteritic anterior ischemic optic neuropathy associated with tirzepatide (Mounjaro®): A case report documented by multimodal imaging].
Guenoun JM, Lachkar Y
J Fr Ophtalmol·2026·Human·PubMed →
Tirzepatide among patients with psoriasis and obesity.
Nicolau J, Sanchís P, Nadal A et al.
Med Clin (Barc)·2026·Human·PubMed →
Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes.
Hoog MM, Vallarino C, Maldonado JM et al.
J Manag Care Spec Pharm·2026·Human·Glycemic Control, Weight Loss·PubMed →
Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine.
Mataraarachchi NE, Dellinger OD 3rd, Babakhanians A
Cureus·2026·Human·PubMed →
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
Ciudin A, Johansson E, Zimner-Rapuch S et al.
Int J Obes (Lond)·2026·Human·PubMed →
Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.
Oh J, Choi JH
Pharmaceuticals (Basel)·2026·Human·PubMed →
Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.
Lin CL, Lin KC, Yu JM et al.
Nat Commun·2026·Human·Glycemic Control·PubMed →
Patient characteristics and early experiences with anti-obesity medications: the CAMP study.
Tewksbury C, Soliva EA, Scheffey K et al.
Front Nutr·2026·Human·PubMed →
Response to Letter to the Editor regarding "Long-Term Mechanical Complications After Lumbar Fusion in Patients Receiving Tirzepatide vs Other GLP-1 Receptor Agonists".
Wang R, Islam H, Karikaran A et al.
Spine (Phila Pa 1976)·2026·Human·PubMed →
The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.
AlAraibi AJ, Shakeeb FN, Alqatta T et al.
Nutr Metab Cardiovasc Dis·2026·Human·PubMed →
Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.
Tu CY, Chen HL, Wu YH et al.
Diabetes Res Clin Pract·2026·Human·PubMed →
Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study.
Waki H, Kaneyuki E, Shingaki T et al.
Endocr Pract·2026·Human·PubMed →
Simultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.
Kolker A
JCEM Case Rep·2026·Human·PubMed →
Exit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.
Stewart KD, Matza LS, Chinthammit C et al.
Diabetes Ther·2026·Human·PubMed →
Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and/or obesity: a retrospective cohort study.
Brouer IC, Zani A, Olbrich H et al.
Front Med (Lausanne)·2026·Human·PubMed →
Real-World Evidence for Existing Anti-Obesity Therapies-The Realities of Treatment Adherence, Tolerability, Access and Patient Satisfaction.
Kassem S
Diabetes Obes Metab·2026·Human·Weight Loss·PubMed →
Association of GLP-1-based therapy with asthma-related outcomes in patients with obesity: a propensity-matched retrospective cohort study.
McCraw CD, Grayeb DR, Gupta N et al.
Expert Rev Respir Med·2026·Human·PubMed →
Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.
Iwamoto Y, Yamashita K, Seki Y et al.
Endocr J·2026·Human·PubMed →
Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.
Hung CT, An CY, Suk CW et al.
J Asthma Allergy·2026·Human·PubMed →
Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome.
Araújo-Vilar D, Vela A, Castro AI et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Postoperative outcomes after total knee arthroplasty in type 2 diabetes mellitus patients receiving semaglutide versus tirzepatide: a propensity score-matched national research network analysis.
Wu KA, Choudhury A, Wu JA et al.
Knee·2026·Human·PubMed →
Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.
Santos-Pereira M, Frutuoso JF, Pereira SS et al.
Front Endocrinol (Lausanne)·2026·Human·Weight Loss·PubMed →
Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.
Patel KS, Fakhoury B, Parmar K et al.
Intest Res·2026·Human·PubMed →
Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.
Albanese R, Tomaselli F, Berkane Y et al.
Aesthetic Plast Surg·2026·Human·PubMed →
Reduced Risk in Melanoma and Nonmelanoma Skin Cancers in Obese Patients on Semaglutide and Tirzepatide.
Alameddine R, Roecker A, Jabin M et al.
Dermatol Surg·2026·Human·PubMed →
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes.
Liao KM, Kuo CY, Wu JY et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control·PubMed →
Tirzepatide-Based Therapy for Multidomain Metabolic Improvement in an Active Duty Service Member: A Case Report.
Kim SK
Cureus·2026·Human·PubMed →
Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.
Tian Z, Willerding JM, Schmidt-Ott KM et al.
EClinicalMedicine·2026·Human·PubMed →
Case report: Tirzepatide-responsive refractory diabetes mellitus in an adult female with prader-willi syndrome.
Li S, Yu J, Wei J et al.
Medicine (Baltimore)·2026·Human·Glycemic Control·PubMed →
Confluent and reticulated papillomatosis improvement with tirzepatide-associated weight loss: A case report.
Bindra H, Paquette G, Levin N
JAAD Case Rep·2026·Human·PubMed →
Metformin-Associated Lactic Acidosis and Relative Euglycemic Ketoacidosis Precipitated by a Glucagon-Like Peptide-1 Receptor Agonist: A Case Report and Literature Review.
Adnani H, Ladiwala Z, Lee M et al.
Kidney360·2026·Human·PubMed →
Adjunctive Treatments for Patients with Type 1 Diabetes Using Automated Insulin Delivery Systems. A Narrative Review.
Kitsios K, Trakatelli CM
Diabetes Technol Ther·2026·Human·PubMed →
Suspected Biphasic Anaphylaxis Following the First Known Dose of Tirzepatide: A Case Report and Brief Review of Reported Hypersensitivity Reactions.
Al-Rashid AH, Ali F
Cureus·2026·Human·PubMed →
Unilateral Graves' Disease Developing During Treatment With Tirzepatide in a Patient With Diabetes: A Case Report.
Deto Y, Hasegawa R, Ino S et al.
Case Rep Endocrinol·2026·Human·PubMed →
Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.
Falcon B, Xie CC, Redline S et al.
J Clin Sleep Med·2026·Human·Sleep Apnea, Weight Loss·PubMed →
Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes.
Fujishiro M, Hagiwara K, Nemoto A et al.
Front Endocrinol (Lausanne)·2026·Human·Glycemic Control, Weight Loss·PubMed →
Acute pancreatitis followed by leukocytoclastic vasculitis induced by tirzepatide: A first case report with this new medication.
Zgolli F, Daly W, Aouinti I et al.
Therapie·2026·Human·PubMed →
Tirzepatide as a possible trigger of bullous pemphigoid: A case report.
Hernández Madrid P, Gotor Rivera A, Alejo Fernández-Baillo JL et al.
J Dtsch Dermatol Ges·2026·Human·PubMed →
Glucagon-like Peptide-1 Receptor Agonists and Dual Incretin Therapies Across HFpEF and Cardiovascular Outcomes Trials in Patients with Obesity.
Belančić A, Klobučar S, Skroče K et al.
Medicina (Kaunas)·2026·Human·Weight Loss, Glycemic Control, Cardiovascular Risk·PubMed →
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity.
Mollero ELM, Dozzani I, Biamonte E et al.
Nutrients·2026·Human·Muscle Recovery, Weight Loss, Glycemic Control·PubMed →
Do Patients Receiving GLP-1 Receptor Agonists for Weight Loss Require Structured Dietetic Care? Lessons from Metabolic and Bariatric Surgery (MBS) Pathways.
Balasubaramaniam V, Scobie M, O'Kane M et al.
Nutrients·2026·Human·Weight Loss·PubMed →
Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study.
Dhali A, Biswas J, Khan F et al.
J Pers Med·2026·Human·PubMed →
When Weight Loss Turns Dangerous: A Case Report of Tirzepatide-Induced Ketoacidosis in a Non-diabetic Woman.
Sadiq H, Amini Z, Husain MM et al.
Cureus·2026·Human·PubMed →
Severe Dumping and Persistent Obesity in a Post-Roux-en-Y Gastric Bypass Patient With a Non-discernible Gastric Pouch and Symptomatic Improvement on Tirzepatide: A Case Report.
Frank AL, Mohli I, Kaur N et al.
Cureus·2026·Human·PubMed →
Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.
Takiyama T, Kitsunai H, Maruyama F et al.
J Diabetes Complications·2026·Human·PubMed →
Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study.
Kır Y, Haymana C, Toros B et al.
J Endocrinol Invest·2026·Human·PubMed →
Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement.
Grewal US, Ear PH, Sonbol MB et al.
Cancer·2026·Human·PubMed →
Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide.
Mortada I, Lee AW, Buckingham D et al.
Ther Adv Cardiovasc Dis·2026·Human·Weight Loss·PubMed →
Real-world effectiveness and safety of low-dose tirzepatide in Japanese people with type 2 diabetes: a multicenter, retrospective, single-arm, observational study-East Shizuoka Tirzepatide (ESTATE) study.
Iwamoto T, Yamasaki N, Nojiri S et al.
Endocr J·2026·Animal·PubMed →
Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.
Rivera Gutierrez RJ, Castaneda R, Verastegui A et al.
J Endocr Soc·2026·Animal·PubMed →